Evidence map›Paper›PMID 26330874›Full record

ArticleIranian journal of pharmaceutical research : IJPR2015

Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital.

Manuela Pérez-Cebrián, María M Morales Suárez-Varela, Isabel Font-Noguera, Emilio Monte-Boquet, Jose Luís Poveda-Andrés, Jose María Martín-Moreno, Nuria Rubio-López, Elias Ruiz-Rojo, Agustín Llopis-González

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Manuela Pérez-CebriánPharmacy Service. University Hospital La Fe, Valencia, Spain.
María M Morales Suárez-VarelaUnit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. ; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ; Center for Public Health Research (CSISP), Valencia, Spain.
Isabel Font-NogueraPharmacy Service. University Hospital La Fe, Valencia, Spain.
Emilio Monte-BoquetPharmacy Service. University Hospital La Fe, Valencia, Spain.
Jose Luís Poveda-AndrésPharmacy Service. University Hospital La Fe, Valencia, Spain.
Jose María Martín-MorenoUnit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain.
Nuria Rubio-LópezUnit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. ; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ; Center for Public Health Research (CSISP), Valencia, Spain.
Elias Ruiz-RojoCIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ; Conselleria de Sanidad, Valencia, Spain.
Agustín Llopis-GonzálezUnit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Spain. ; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ; Center for Public Health Research (CSISP), Valencia, Spain.
Universitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary.

Indexed as

Approval of indicationsDrug-related problemsDrug safety evaluationLinezolid prescriptionUniversity hospital

Identifiers

PMID26330874
PMCPMC4518114
OpenAlexW2116386177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.